Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis

<p>Outcomes of treatment for the patient subgroup with MET overexpression</p>

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkki:	Chong Kin Liam (15331321) (author)
Eará dahkkit:	Azura Rozila Ahmad (15331324) (author), Te-Chun Hsia (15331327) (author), Jianying Zhou (15331330) (author), Dong-Wan Kim (15036467) (author), Ross Andrew Soo (15331333) (author), Ying Cheng (15331336) (author), Shun Lu (15331339) (author), Sang Won Shin (15331342) (author), James Chih-Hsin Yang (15048002) (author), Yiping Zhang (15331345) (author), Jun Zhao (11571833) (author), Karin Berghoff (15331348) (author), Rolf Bruns (15331351) (author), Andreas Johne (15331354) (author), Yi-Long Wu (11678896) (author)
Almmustuhtton:	2025
Fáttát:	Cancer Therapeutic Research and Development Clinical Research and Trials Chemotherapy Clinical Trial Results Clinical-Stage Research Drug Resistance Lung Cancer Precision Medicine Small Molecule Agents
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Dahkki: Chong Kin Liam (15331321)
Almmustuhtton: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Dahkki: Chong Kin Liam (15331321)
Almmustuhtton: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Dahkki: Chong Kin Liam (15331321)
Almmustuhtton: (2025)

Figure 1 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
Dahkki: Christian Rolfo (17314293)
Almmustuhtton: (2025)

Figure 2 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
Dahkki: Christian Rolfo (17314293)
Almmustuhtton: (2025)

Figure 3 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
Dahkki: Christian Rolfo (17314293)
Almmustuhtton: (2025)

Figure 4 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
Dahkki: Christian Rolfo (17314293)
Almmustuhtton: (2025)

Table 1 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
Dahkki: Christian Rolfo (17314293)
Almmustuhtton: (2025)

Table 2 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
Dahkki: Christian Rolfo (17314293)
Almmustuhtton: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Figure 1 from Deep Learning Predicts <i>EGFR</i> Mutation Status from Histology Images in Non–Small Cell Lung Cancer
Dahkki: Jongchan Park (22800721)
Almmustuhtton: (2025)

Figure 2 from Deep Learning Predicts <i>EGFR</i> Mutation Status from Histology Images in Non–Small Cell Lung Cancer
Dahkki: Jongchan Park (22800721)
Almmustuhtton: (2025)

Figure 3 from Deep Learning Predicts <i>EGFR</i> Mutation Status from Histology Images in Non–Small Cell Lung Cancer
Dahkki: Jongchan Park (22800721)
Almmustuhtton: (2025)

Table 1 from Deep Learning Predicts <i>EGFR</i> Mutation Status from Histology Images in Non–Small Cell Lung Cancer
Dahkki: Jongchan Park (22800721)
Almmustuhtton: (2025)

Table 2 from Deep Learning Predicts <i>EGFR</i> Mutation Status from Histology Images in Non–Small Cell Lung Cancer
Dahkki: Jongchan Park (22800721)
Almmustuhtton: (2025)

Table 3 from Deep Learning Predicts <i>EGFR</i> Mutation Status from Histology Images in Non–Small Cell Lung Cancer
Dahkki: Jongchan Park (22800721)
Almmustuhtton: (2025)

Supplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
Dahkki: Takafumi Koyama (15035714)
Almmustuhtton: (2025)

Supplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
Dahkki: Takafumi Koyama (15035714)
Almmustuhtton: (2025)

Supplementary Table S5A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
Dahkki: Takafumi Koyama (15035714)
Almmustuhtton: (2025)

Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
Dahkki: Takafumi Koyama (15035714)
Almmustuhtton: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Dahkki: Srivandana Akshintala (16610490)
Almmustuhtton: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Dahkki: Srivandana Akshintala (16610490)
Almmustuhtton: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Dahkki: Tom Wei-Wu Chen (15053003)
Almmustuhtton: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Dahkki: Tom Wei-Wu Chen (15053003)
Almmustuhtton: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Dahkki: Tom Wei-Wu Chen (15053003)
Almmustuhtton: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Dahkki: Tom Wei-Wu Chen (15053003)
Almmustuhtton: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Dahkki: Tom Wei-Wu Chen (15053003)
Almmustuhtton: (2025)

Figure 1 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
Dahkki: Diana M. Carvalho (5608127)
Almmustuhtton: (2025)

Figure 2 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
Dahkki: Diana M. Carvalho (5608127)
Almmustuhtton: (2025)